Transactions in Zealand Pharma shares and/or related securities by persons discharging managerial responsibilities and/or their closely associated persons

On April 19, 2026, Zealand Pharma A/S, a biotechnology company specializing in metabolic health, announced that it had received information regarding transactions in its shares and related securities conducted by individuals in managerial positions and their closely associated persons. The specifics of the transactions were not disclosed, including the deal value. Zealand Pharma is listed on Nasdaq under the ticker symbol ZEAL and has been a key player in the biotechnology sector for over 25 years.

Zealand Pharma focuses on developing innovative medicines aimed at treating obesity and other metabolic disorders. With a robust foundation in peptide research and development, the company has successfully advanced more than ten drug candidates into clinical development, with two products already on the market and three candidates in late-stage development. The firm leverages a proprietary data platform that integrates advanced data-driven methodologies, including artificial intelligence and machine learning, to enhance its research capabilities.

The biotechnology sector, particularly in the realm of metabolic health, has seen increasing investment and interest as global health challenges related to obesity and metabolic diseases continue to rise. Zealand Pharma's strategic focus on this niche, combined with its extensive R&D expertise, positions it well to capitalize on the growing demand for effective treatments. The company's collaborations with major pharmaceutical and biotechnology partners further bolster its potential for innovation and market reach.

The recent transactions involving managerial personnel may reflect confidence in Zealand Pharma's future growth prospects. Such activities often indicate that insiders believe in the company's trajectory and are willing to invest in their own organization, which can be a positive signal to the market. As the company continues to advance its pipeline and explore new partnerships, its ability to navigate the competitive landscape will be crucial for sustaining momentum.

Overall, Zealand Pharma's ongoing commitment to transforming metabolic health through innovative therapies aligns with broader trends in the biotechnology sector. As the demand for effective obesity treatments escalates, companies like Zealand Pharma that are equipped with strong R&D capabilities and strategic partnerships are likely to play a significant role in shaping the future of healthcare in this domain. The implications of these insider transactions may serve as a precursor to further developments in the company's growth and investment landscape.